d********2 发帖数: 1042 | 1 MNKD - 09:37:46
Bought 182s @ $6.1899 - Total: $1,126.56
MNKD - 09:37:46
Bought 2418s @ $6.1899 - Total: $14,967.18
MNKD - 09:37:46
Bought 100s @ $6.18 - Total: $625.00
MNKD - 09:37:46
Bought 600s @ $6.1899 - Total: $3,713.94
MNKD - 09:37:46
Bought 100s @ $6.18 - Total: $618.00
MNKD - 09:37:46
Bought 200s @ $6.18 - Total: $1,236.00
MNKD - 09:37:46
Bought 400s @ $6.1899 - Total: $2,475.96 |
|
t*******o 发帖数: 1464 | 2 5/21
Interesting Options Volume for MannKind Corporation (MNKD)
NEW YORK (Market Intellisearch) -- MNKD options saw interesting call
activity today. A total of 1,967 put and 8,881 call contracts were traded
raising a low Put/Call volume alert. Today's traded Put/Call ratio is 0.22.
There were 4.51 calls traded for each put contract.
Options can be used as predictors of stock behavior. Investors can use Put/
Call ratios as technical indicators to read for signs of institutional
sentiment. The Put... 阅读全帖 |
|
D*******0 发帖数: 2523 | 3 FNMA, MNKD 都是赌,
MNKD几乎能赌赢,FNMA赢的几率也大。
PLUG顺势而为,还有momentum, 象TSLA一样,架不住大家喜欢。
其实我并不是很喜欢,大概明天卖掉。买它纯粹找刺激。
JCP抽插好几次了,今天想了半天没卖。
BAC应该和存CD一样保险,长期一定是涨的。所以我的cash都买成BAC。 |
|
f**********g 发帖数: 2252 | 4 来自主题: _Stockcafeteria版 - MNKD MannKind Says FDA Review Of Afrezza To Take Four More Weeks
0 minutes ago - Dow Jones News
Related Companies
Symbol Last %Chg
MNKD 7.97 0.00%
As of 4:00 PM ET 12/27/10
DOW JONES NEWSWIRES
MannKind Corp. (MNKD) said the U.S. Food and Drug Administration's review of
its new drug application for its inhaled-insulin product for diabetics will
require four additional weeks.
The biopharmaceutical company, which has no products on the market currently
, had been expecting FDA approval of Afrezza by Wed... 阅读全帖 |
|
f**********g 发帖数: 2252 | 5 MannKind Says FDA Review Of Afrezza To Take Four More Weeks
0 minutes ago - Dow Jones News
Related Companies
Symbol Last %Chg
MNKD 7.97 0.00%
As of 4:00 PM ET 12/27/10
DOW JONES NEWSWIRES
MannKind Corp. (MNKD) said the U.S. Food and Drug Administration's review of
its new drug application for its inhaled-insulin product for diabetics will
require four additional weeks.
The biopharmaceutical company, which has no products on the market currently
, had been expecting FDA approval of Afrezza by Wed... 阅读全帖 |
|
b*****h 发帖数: 783 | 6 CEO Mann 一直很挺mnkd,不过这些transaction是以前就签好的协议,buy match
Seaside 88的短期投资。而且这些股票是直接用mnkd欠ceo的钱来抵的。
再一个星期就出最后结果了。呵呵,准备100股支持Mann 执着的biotech开发精神。 |
|
f**********g 发帖数: 2252 | 7 MannKind Says FDA Review Of Afrezza To Take Four More Weeks
0 minutes ago - Dow Jones News
Related Companies
Symbol Last %Chg
MNKD 7.97 0.00%
As of 4:00 PM ET 12/27/10
DOW JONES NEWSWIRES
MannKind Corp. (MNKD) said the U.S. Food and Drug Administration's review of
its new drug application for its inhaled-insulin product for diabetics will
require four additional weeks.
The biopharmaceutical company, which has no products on the market currently
, had been expecting FDA approval of Afrezza by Wed... 阅读全帖 |
|
b*****h 发帖数: 783 | 8 CEO Mann 一直很挺mnkd,不过这些transaction是以前就签好的协议,buy match
Seaside 88的短期投资。而且这些股票是直接用mnkd欠ceo的钱来抵的。
再一个星期就出最后结果了。呵呵,准备100股支持Mann 执着的biotech开发精神。 |
|
y*****l 发帖数: 5997 | 9 参赛ID:
yaokarl
参赛picks(限制两pick,不允许future/option/外汇):
MNKD
Pick#1, Long/Short,权重比,LMT(opt) 如:Long,50%:
Long,100%
Pick#2, Long/Short,权重比,LMT(opt) 如:Long,50%:
选股理由:
比赛跨度(半月赛 or 季度赛):
半月赛 |
|
w*******g 发帖数: 9932 | 10 look like you are the only other MNKD long here. I had made some paper
profit these days. How about you?
Do you think I should dump some shares before the fateful day? |
|
d*****n 发帖数: 433 | 11 听说MNKD被完全据了,
没有制药专利权的生物制药小公司基本就是垃圾了。。。。 |
|
m******u 发帖数: 12400 | 12 是500K不是50K,楼上看错了。
发信人: g8 (♡♡Bush♡♡), 信区: Stock
标 题: Re: 关注MNKD!
发信站: BBS 未名空间站 (Wed Jun 20 11:47:18 2012, 美东)
50k的量,让大鳄情何以堪~ |
|
|
r***l 发帖数: 9084 | 14 我没有说mnkd不会赚钱,这次买的人会赚很多我一点不奇怪,当然如果亏很多我也不惊
讶。但大仓位做小bio/pharm,长远看散户的胜算微乎其微。原来c-帅再位的时候,不
炒小bio/pharm是顶置的,是反复提醒青蛙的炒股原则之一。
again, 包括主席的arna,和过去的renn,看图我也觉的主席的看法挺英明的,但对我自
己来说,我的炒股纪律是不碰这些股票的。 对于大部分散户来说,炒股遵守自己的纪
律走在一条正确的道路上,比捡了几个暴涨的pick要重要的多。 |
|
t**********w 发帖数: 478 | 15 无脑跟pick当然比较危险
但是这次mnkd的图来看 突破的可能性还是很大的
kwist大牛上来给大家推荐pick 大家可以根据自己的情况决定要不要跟 愿意来跟大家
分享总是好事情 当然rival大牛提醒大家也是好事情啦 两个人的观点不冲突嘛 都是为
我们青蛙谋福利的~~ |
|
k***t 发帖数: 769 | 16 哈哈哈,有赚就好。我这两天先跑了,然后等他回调以后再进。个人认为MNKD的东西很
有前途。 |
|
y******1 发帖数: 730 | 17 【 以下文字转载自 pennystock 俱乐部 】
发信人: yoren001 (Ajie), 信区: pennystock
标 题: MNKD怎么了
发信站: BBS 未名空间站 (Tue Jun 18 14:14:28 2013, 美东)
为什么暴跌?有什么消息么 |
|
|
l********i 发帖数: 2503 | 19 发信人: longlaoshi (最近喜欢钓鱼), 信区: Pharmstocks
标 题: Re: 龙老师看mnkd是不是个fraud
发信站: BBS 未名空间站 (Thu Aug 15 16:19:35 2013, 美东)
不奇怪,前期涨太多了,都跑了吧。再有,市场好象对这个药不感冒,不看好,FDA批
的可能性比较小,即使批了也没市场,辉瑞有个类似的已经撤销了 |
|
|
x*j 发帖数: 271 | 21 MNKD那东西本身就不行啊。就一个圈钱烧钱的万一。我和认识的多年的糖尿病人聊天人
家都说宁愿注射也不愿意用这个。 |
|
m******3 发帖数: 734 | 22 pfizer之前就有inhale insulin. 后来发现可能导致肺癌。那个药不卖了,其他公司的
inhale insulin的研究也都停了。 只有MNKD还在做 |
|
m******3 发帖数: 734 | 23 pfizer之前就有inhale insulin. 后来发现可能导致肺癌。那个药不卖了,其他公司的
inhale insulin的研究也都停了。 只有MNKD还在做 |
|
|
s******t 发帖数: 213 | 25 看ormp的口服胰岛素!
如果没有ormp,这个是很有前途的。 以前公司失败有各种各样的原因,既贵又笨重难
用,所以批准了却没人买。 mnkd的产品似乎很好用,很方便。 我一开始很看好,后来
了解到ormp之后就动摇了。 |
|
|
n*****3 发帖数: 66 | 27 MNKD在大千很受追捧,这里的大牛好像不关注? |
|
n****8 发帖数: 294 | 28
adam feuerstein:
I'll say it now....
MNKD and its supporters were right about Afrezza approval.
I was wrong.
Still waiting for T2 vote but it will also be positive. |
|
R******a 发帖数: 1195 | 29 炒股几年来第二次赌FDA,去年冬天AMRN压大赌输了,仓位不大但也损失了两盏银灯。这
次MNKD运气不错,现有1200股。昨天庄家疯狂打压到4,竟然没割肉,还加了一倍多仓
。以后不能再赌了,发贴为誓。 |
|
R******a 发帖数: 1195 | 30 MNKD的结局会不会还是收购?老AllMann拿钱走人安度晚年去吧,也算一代传奇人物,
急流勇退不失一个好的选择。 |
|
D*******0 发帖数: 2523 | 31 仓位只有五支股:
FNMA 1/6
PLUG. 1/6
MNKD. 1/6
JCP. 1/6
BAC. 1/3
是不是风险太大?呵呵。
明天感觉大起大落的一天! |
|
|
Q*****T 发帖数: 558 | 33 没赶上之前翻番。不过后面也有小机会。
MNKD
跌倒6左右可以捞一下,不确定能不能跌倒6以下。七月十五前后FDA公布approval可以
稳定到7~7.5 被哄抬冲一冲上8,9也是可能的--保守的预估。
没有什么大风险,不用设止损。除非爆出来递交给FDA的材料跟目前报出来的严重不符
,7.15被disapproved,这种时候就要果断割肉。目前来看这个可能性也不太大。
另外如果FDA approved,这个股票可以长期持有来着。长期持有的最大风险在于这个胰
岛素inhaler投放市场一段时间是否被爆出来有严重肺癌隐患。目前数据来看肺癌风险
没有明显到令人担忧的地步。
Disclaimer:入市谨慎,风险自负 |
|
D*******0 发帖数: 2523 | 34 It's kind of boring to see MNKD up everyday. |
|
D*******0 发帖数: 2523 | 35 It's kind of boring to see MNKD up everyday. |
|
a*********d 发帖数: 194 | 36 仓位怎么样了?
这货我老两三年前玩过小赚,还在股版pump过两块钱,就没再碰,C帅当年对小药股的
指示和教导这么多年了一直牢记在心和警示。
发信人: annarealdad (annarealdad), 信区: Stock
标 题: Re: mnkd今天涨
发信站: BBS 未名空间站 (Fri Mar 28 09:52:59 2014, 美东)
这个垃圾股,去年我大概从3块跟到7块。
结果股版上了一万多个call,我立马下车跑了。现在看好像跑的还行。
http://www.mitbbs.com/article_t/Stock/34769315.html |
|
|
|
b*****h 发帖数: 783 | 39 mnkd准备发100m$的convertiable notes,股价盘后进一步下跌。。。 |
|
b*****h 发帖数: 783 | 40 100m convertible note 的 convert rate大概是6.8$/share, 当时借给boa的8M
short 用的股票在45天后要被归还, 这些note holder可以从市场买股票来归还,或者
用手里的note来变换。
mnkd这一阵眼花缭乱的融资已经把股价打压下来很多。他的吸入式insulin 产品
AFREZZA 面对的市场大,股价在稳定后会有上升空间。 |
|
|
f*******0 发帖数: 221 | 42 MNKD -- the alleged Afrezza data fraud occurred at clinical trials sites in
Russia and Bulgaria, according to the lawsuit. |
|
b*****h 发帖数: 783 | 43 1.not new, already claimed in 10-Q,
2."the Company had completed an internal investigation of his claims and
retained an independent outside firm to conduct an independent investigation
of his claims. Neither investigation found any basis for his claims. The
Company believes that the allegations in the complaint are without merit and
intends to defend against them vigorously."
anyway, this will add pain to mnkd in short time.
in |
|
f*******0 发帖数: 221 | 44
and
investigation
The
merit and
MNKD has been accused for data fraud twice. |
|
b*****h 发帖数: 783 | 45 对mnkd有几个concerns,1。他很缺钱,debet 大 2。他发行的股票量有点大了。
3。pfe的吸入式Exubera marketing 失败让不少人对这个东西心存疑虑。 |
|
b*****h 发帖数: 783 | 46 现在这种肥手指越来越多了。dndn,avnr, pozn, 不过前面出现过肥手指的都是fda批的。看看mnkd的最后命运如何。 |
|
f*******0 发帖数: 221 | 47 from adam:
adamfeuerstein Adam Feuerstein
$MNKD -- looks like another year delay to me at minimum. Planning new trials
, conducting new trials, data analysis, resubmit + 6 mos. review |
|
C*******i 发帖数: 2131 | 48 MNKD is dead. Everything starts over again. How low can it go? |
|
b*****h 发帖数: 783 | 49 现在这种肥手指越来越多了。dndn,avnr, pozn, 不过前面出现过肥手指的都是fda批的。看看mnkd的最后命运如何。 |
|
f*******0 发帖数: 221 | 50 from adam:
adamfeuerstein Adam Feuerstein
$MNKD -- looks like another year delay to me at minimum. Planning new trials
, conducting new trials, data analysis, resubmit + 6 mos. review |
|